Literature DB >> 32123103

Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation.

Susanna K Elledge1, Hai L Tran1, Alec H Christian2, Veronica Steri3,4, Byron Hann3,4, F Dean Toste2, Christopher J Chang2,5,6, James A Wells7,8.   

Abstract

The field of chemical modification of proteins has been dominated by random modification of lysines or more site-specific labeling of cysteines, each with attendant challenges. Recently, we have developed oxaziridine chemistry for highly selective modification of methionine called redox-activated chemical tagging (ReACT) but have not broadly tested the molecular parameters for efficient and stable protein modification. Here we systematically scanned methionines throughout one of the most popular antibody scaffolds, trastuzumab, used for antibody engineering and drug conjugation. We tested the expression, reactivities, and stabilities of 123 single engineered methionines distributed over the surface of the antibody when reacted with oxaziridine. We found uniformly high expression for these mutants and excellent reaction efficiencies with a panel of oxaziridines. Remarkably, the stability to hydrolysis of the sulfimide varied more than 10-fold depending on temperature and the site of the engineered methionine. Interestingly, the most stable and reactive sites were those that were partially buried, presumably because of their reduced access to water. There was also a 10-fold variation in stability depending on the nature of the oxaziridine, which was determined to be inversely correlated with the electrophilic nature of the sulfimide. Importantly, the stabilities of the best analogs were sufficient to support their use as antibody drug conjugates and potent in a breast cancer mouse xenograft model over a month. These studies provide key parameters for broad application of ReACT for efficient, stable, and site-specific antibody and protein bioconjugation to native or engineered methionines.

Entities:  

Keywords:  antibody drug conjugate; bioconjugation; chemical biology; oxaziridine methionine chemistry; protein engineering

Year:  2020        PMID: 32123103      PMCID: PMC7084160          DOI: 10.1073/pnas.1920561117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

2.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

3.  In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.

Authors:  Penny Bryant; Martin Pabst; George Badescu; Matthew Bird; William McDowell; Estera Jamieson; Julia Swierkosz; Kosma Jurlewicz; Rita Tommasi; Korinna Henseleit; XiaoBo Sheng; Nicolas Camper; Anais Manin; Katarzyna Kozakowska; Karolina Peciak; Emmanuelle Laurine; Ruslan Grygorash; Andrew Kyle; David Morris; Vimal Parekh; Amrita Abhilash; Ji-Won Choi; Jeff Edwards; Mark Frigerio; Matthew P Baker; Antony Godwin
Journal:  Mol Pharm       Date:  2015-05-05       Impact factor: 4.939

4.  CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.

Authors:  Helena Persson; Wei Ye; Amy Wernimont; Jarrett J Adams; Akiko Koide; Shohei Koide; Robert Lam; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2012-12-03       Impact factor: 5.469

5.  Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.

Authors:  Xuan Gao; Junyan A Ji; Karthik Veeravalli; Y John Wang; Taylor Zhang; William Mcgreevy; Kai Zheng; Robert F Kelley; Michael W Laird; Jun Liu; Mary Cromwell
Journal:  J Pharm Sci       Date:  2014-08-29       Impact factor: 3.534

6.  Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions.

Authors:  C F Meares; M J McCall; D T Reardan; D A Goodwin; C I Diamanti; M McTigue
Journal:  Anal Biochem       Date:  1984-10       Impact factor: 3.365

Review 7.  Antibody-drug conjugates: recent advances in conjugation and linker chemistries.

Authors:  Kyoji Tsuchikama; Zhiqiang An
Journal:  Protein Cell       Date:  2016-10-14       Impact factor: 14.870

8.  Simultaneous epitope and transcriptome measurement in single cells.

Authors:  Marlon Stoeckius; Christoph Hafemeister; William Stephenson; Brian Houck-Loomis; Pratip K Chattopadhyay; Harold Swerdlow; Rahul Satija; Peter Smibert
Journal:  Nat Methods       Date:  2017-07-31       Impact factor: 28.547

Review 9.  The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia.

Authors:  Pamela C Egan; John L Reagan
Journal:  Onco Targets Ther       Date:  2018-11-22       Impact factor: 4.147

10.  Simultaneous Multiplexed Measurement of RNA and Proteins in Single Cells.

Authors:  Spyros Darmanis; Caroline Julie Gallant; Voichita Dana Marinescu; Mia Niklasson; Anna Segerman; Georgios Flamourakis; Simon Fredriksson; Erika Assarsson; Martin Lundberg; Sven Nelander; Bengt Westermark; Ulf Landegren
Journal:  Cell Rep       Date:  2015-12-31       Impact factor: 9.423

View more
  7 in total

1.  Selenomethionine as an expressible handle for bioconjugations.

Authors:  Dillon T Flood; Jordi C J Hintzen; Kyle W Knouse; David E Hill; Chenxi Lu; Philip A Cistrone; Jason S Chen; Takanori Otomo; Philip E Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-23       Impact factor: 11.205

2.  Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis.

Authors:  Dan He; Huijin Feng; Belen Sundberg; Jiaxing Yang; Justin Powers; Alec H Christian; John E Wilkinson; Cian Monnin; Daina Avizonis; Craig J Thomas; Richard A Friedman; Michael D Kluger; Michael A Hollingsworth; Paul M Grandgenett; Kelsey A Klute; F Dean Toste; Christopher J Chang; Iok In Christine Chio
Journal:  Mol Cell       Date:  2022-06-24       Impact factor: 19.328

3.  Biomolecule-Compatible Dehydrogenative Chan-Lam Coupling of Free Sulfilimines.

Authors:  Tingting Meng; Lucille A Wells; Tianxin Wang; Jinyu Wang; Shishuo Zhang; Jie Wang; Marisa C Kozlowski; Tiezheng Jia
Journal:  J Am Chem Soc       Date:  2022-06-29       Impact factor: 16.383

4.  Chemical Diversification of Simple Synthetic Antibodies.

Authors:  Mariha Islam; Haixing P Kehoe; Jacob B Lissoos; Manjie Huang; Christopher E Ghadban; Greg Berumen Sánchez; Hanan Z Lane; James A Van Deventer
Journal:  ACS Chem Biol       Date:  2021-01-22       Impact factor: 5.100

5.  Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.

Authors:  Shion A Lim; Jie Zhou; Alexander J Martinko; Yung-Hua Wang; Ekaterina V Filippova; Veronica Steri; Donghui Wang; Soumya G Remesh; Jia Liu; Byron Hann; Anthony A Kossiakoff; Michael J Evans; Kevin K Leung; James A Wells
Journal:  J Clin Invest       Date:  2022-02-15       Impact factor: 14.808

6.  Are Methionine Sulfoxide-Containing Proteins Related to Seed Longevity? A Case Study of Arabidopsisthaliana Dry Mature Seeds Using Cyanogen Bromide Attack and Two-Dimensional-Diagonal Electrophoresis.

Authors:  Ewa Marzena Kalemba; Benoît Valot; Dominique Job; Christophe Bailly; Patrice Meimoun
Journal:  Plants (Basel)       Date:  2022-02-21

Review 7.  Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development.

Authors:  Eugene M Obeng; Isaac Fianu; Michael K Danquah
Journal:  Nano Today       Date:  2022-08-04       Impact factor: 18.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.